Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Brian Peck

Rheumatology Waterbury, CT Medical Doctor

NPI 1629036868 CMS profile 27606

1389 W Main St, Suite 120, Waterbury, CT 06708

Open in the dashboard

General payments

$1,591

108 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Brian Peck of Waterbury, CT is reported in the CMS Open Payments database as having received $1,591 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $168 6
2021 General $504 29
2020 General $544 33
2019 General $374 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Peck
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Brian Peck were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Brian Peck Rheumatology median Middle half National median
2019 $374 $744 $153–$2,687 $163
2020 $544 $462 $98–$2,027 $114
2021 $504 $531 $101–$2,153 $132
2022 $168 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Amgen Inc. $381 27 payments
  2. AbbVie, Inc. $293 15 payments
  3. Janssen Biotech, Inc. $280 32 payments
  4. Mallinckrodt Hospital Products Inc. $131 4 payments
  5. GlaxoSmithKline, LLC. $97 5 payments
  6. Collegium Pharmaceutical, Inc. $64 3 payments
  7. Genentech USA, Inc. $50 4 payments
  8. Novartis Pharmaceuticals Corporation $38 3 payments
  9. AstraZeneca Pharmaceuticals LP $38 2 payments
  10. RedHill Biopharma Inc. $36 2 payments
  11. Other $183 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $1,531 107 payments
  2. Education $60 1 payment
Products named General payments · program years 2019–2022
  1. SIMPONI ARIA $256 27 payments
  2. RINVOQ $237 12 payments
  3. STELARA $210 22 payments
  4. ACTHAR $131 4 payments
  5. Enbrel Inflammation $127 11 payments
  6. Enbrel Inflammation $126 9 payments
  7. BENLYSTA $97 5 payments
  8. SIMPONI $97 9 payments
  9. Prolia $95 6 payments
  10. EVENITY $87 5 payments
  11. Other $711 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record